

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q2 15-16	Q2 14-15	% Gr y-y	YTD 15-16	YTD 14-15	% Gr y-y
Home Markets	18,078	15,475	16.8%	35,897	29,933	19.9%
US Formulations	10,038	8,020	25.2%	19,888	15,185	31.0%
India Formulations	7,513	6,808	10.3%	14,928	13,557	10.1%
Latin America Formulations	527	647	-18.5%	1,080	1,191	-9.3%
Other Markets and Businesses	6,103	5,589	9.2%	12,501	11,698	6.9%
Europe Formulations	652	777	-16.1%	1,488	1,789	-16.8%
Emerging Markets Formulations	1,198	887	34.9%	2,452	1,938	26.6%
Consumer Wellness	1,116	1,101	1.4%	2,223	2,176	2.1%
Animal Health & Others	807	801	0.7%	1,569	1,577	-0.5%
APIs	907	887	2.3%	1,887	1,894	-0.4%
JVs and Alliances	1,423	1,136	25.3%	2,882	2,325	24.0%
Grand Total	24,180	21,064	14.8%	48,398	41,631	16.3%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q2 15-16	Q2 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Other Operating Income	857	445	92.6%	2,080	742	180.3%
Royalty Income	62	229	-73.1%	101	289	-65.1%
Net Gain on foreign currency transactions and translation (Refer Note below)	127	-17	838.9%	199	3	5868.9%
Others	668	233	186.6%	1,781	450	295.9%

Note : There was a net gain of Rs. 166 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q2 15-16. Thus, on aggregate level, there was a gain of Rs. 293 Mio. on operating transactions (above EBIDTA line) in Q2 15-16 vs loss of Rs. 1 Mio. in Q2 14-15. See details below for more clarity.

Rs. Mio.	Q2 15-16	Q2 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Other Income	237	146	62.4%	446	250	78.1%
Interest & Dividend income	162	107	51.5%	296	192	54.6%
Profit on sale of investments	38	23	61.8%	44	27	64.1%
Others	37	16	134.1%	106	32	230.1%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q2 15-16	Q2 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
A. On operating transactions (above EBIDTA line)	-293	1	-24655.6%	-497	-46	-980.4%
a. Included in other income	-127	17	-838.9%	-199	-3	-6533.3%
c. Included in cost of goods	-166	-16	-937.5%	-298	-43	-593.0%
d. Included in other expenses						
B. On Foreign Currency Borrowings (part of interest cost)	21	12	75.0%	43	-1	4400.0%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-272	13	-2162.0%	-454	-47	-866.0%

Details of R&D Expenses

Rs. Mio.	Q2 15-16	Q2 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Total R&D Expenses	1,730	1,179	46.8%	3,414	2,235	52.7%

Consolidated Capex for H1 FY16

**Rs. 3429
Mio.**

R&D capex included in above for H1 FY16

**Rs. 89
Mio.**